Skip to main content

Table 1 Osteoprotegerin genotype frequencies in prostate cancer patients (PCa) and control males

From: A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer

149 T/C

  

149 T/C Genotype

C allele frequency (%)

Study group

Total no.

CC

TC

TT

 

PCaa

361

4 (1.1)

84 (23.3)

273 (75.6)

12.742

   Stageb

     

   A

24

1 (4.2)

5 (20.8)

18 (75.0)

14.583

   B

184

1 (0.5)

40 (21.7)

143 (77.8)

11.413

   C

56

1 (1.8)

16 (28.6)

39 (69.6)

16.071

   D

97

1 (1.0)

23 (23.7)

73 (75.3)

12.886

   Organ confined PCa

208

2 (1.0)

45 (21.6)

161 (77.4)

11.778

   Extraprostatic PCa

153

2 (1.3)

39 (25.5)

112 (73.2)

14.052

   Localized Pca

264

3 (1.1)

61 (23.1)

200 (75.8)

12.689

   Metastatic Pca

97

1 (1.0)

23 (23.7)

73 (75.3)

12.887

Gradec

     

   Low/Intermediate

257

1 (0.4)

55 (21.4)

201 (78.2)

11.089

   High

104

3 (2.9)

29 (27.9)

72 (69.2)

16.826

Control

195

3 (1.5)

37 (19.0)

155 (79.5)

11.026

950 T/C

  

950 T/C Genotype (%)

C allele frequency (%)

Study group

Total no.

CC

TC

TT

 

PCaa

361

63 (17.4)

162 (44.9)

136 (37.7)

39.889

   Stageb

     

   A

24

8 (33.3)

8 (33.3)

8 (33.3)

50

   B

184

36 (19.6)

84 (45.6)

64 (34.8)

42.391

   C

56

9 (16.0)

30 (53.6)

17 (30.4)

42.857

   D

97

11 (10.3)

39 (41.2)

47 (48.5)

30.927

   Organ confined PCa

208

44 (21.2)

92 (44.2)

72 (34.6)

43.269

   Extraprostatic PCa

153

19 (12.4)

70 (45.8)

64 (41.8)

35.294

   Localized Pca

264

53 (20.0)

122 (46.3)

89 (33.7)

43.181

   Metastatic Pca

97

11 (10.4)

39 (41.2)

47 (48.4)

30.927

Gradec

     

   Low/Intermediate

257

48 (18.7)

116 (45.1)

93 (36.2)

41.245

   High

104

15 (14.4)

46 (44.3)

43 (41.3)

36.538

Control

195

29 (14.9)

98 (50.2)

68 (34.9)

40

  1. a Prostate cancer versus control, P = 0.939 and 0.294 by the chi-square test for 149 T/C and 950 T/C, respectively.
  2. b According to the Whitmore-Jewett system. Stage A = T1a-bN0M0, Stage B = T1c-2N0M0, Stage C = T3–4N0M0 and Stage D = T1–4N1M0–1 or T1–4N0–1M1. Localized PCa (Stage A + B + C) versus Metastatic PCa (Stage D) P = 0.931 and 0.005 by the chi-square test for 149 T/C and 950T/C, respectively. Organ confined (Stage A + B) versus Extraprostatic PCa (Stage C + D), P = 0.346 and 0.021 by the chi-square test for 149 T/C and 950T/C, respectively.
  3. c Low grade = well-differentiated carcinoma (WHO) or Gleason score 2–4 carcinoma, Intermediate grade = moderately differentiated carcinoma (WHO) or Gleason score 5–7 carcinoma, High grade = poorly differentiated carcinoma (WHO) or Gleason score 8–10 carcinoma. C allele frequency, P = 0.884 and 0.520 by the chi-square test for 149 T/C and 950 T/C, respectively.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us